论文部分内容阅读
目的:评价奥硝唑三联疗法治疗幽门螺杆菌(Hp)相关的消化性溃疡病的疗效及其安全性。方法:将Hp检测阳性,内镜检查为活动期十二指肠溃疡的患者分为治疗组:雷贝拉唑,克拉霉素,奥硝唑;对照组:雷贝拉唑,克拉霉素,替硝唑;连用1周。然后两组继续使用雷贝拉唑1周。第28天复查内镜并检测Hp。结果:疗程结束后第28天内镜检查结果和Hp检测结果两组对比无统计学差异。结论:雷贝拉唑、克拉霉素、奥硝唑三联疗法对Hp相关的消化性溃疡病具有良好的治疗作用和安全性。
Objective: To evaluate the efficacy and safety of ornidazole triple therapy in the treatment of peptic ulcer disease associated with Helicobacter pylori (Hp). Methods: Patients with positive Hp test and endoscopic examination of active duodenal ulcer were divided into treatment group: rabeprazole, clarithromycin and ornidazole; control group: rabeprazole, clarithromycin, Tinidazole; used for 1 week. Then both groups continued to use rabeprazole for 1 week. On the 28th day, we examined the endoscope and detected Hp. Results: There was no significant difference between the endoscopic examination results and the Hp test results on the 28th day after the end of treatment. Conclusion: Rabeprazole, clarithromycin, ornidazole triple therapy for Hp-related peptic ulcer disease has a good therapeutic effect and safety.